Raddatz, Dirk

[["dc.bibliographiccitation.firstpage","S8"],["dc.bibliographiccitation.issue","S1"],["dc.bibliographiccitation.journal","Annals of translational medicine"],["dc.bibliographiccitation.lastpage","S8"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Claudia Gollisch, Katja Susanne"],["dc.contributor.author","Raddatz, Dirk"],["dc.date.accessioned","2020-12-10T18:42:53Z"],["dc.date.available","2020-12-10T18:42:53Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.21037/atm.2019.09.67"],["dc.identifier.eissn","2305-5847"],["dc.identifier.issn","2305-5839"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78121"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Endoscopic intragastric balloon: a gimmick or a viable option for obesity?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1559"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","European Journal of Gastroenterology & Hepatology"],["dc.bibliographiccitation.lastpage","1565"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Bremer, Sebastian C.B."],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Neesse, Albrecht"],["dc.date.accessioned","2021-04-14T08:24:50Z"],["dc.date.available","2021-04-14T08:24:50Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1097/MEG.0000000000001675"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81439"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0954-691X"],["dc.title","Noninvasive assessment of liver fibrosis in a real-world cohort of patients with known or suspected chronic liver disease using 2D-shear wave elastography"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4246"],["dc.bibliographiccitation.issue","19"],["dc.bibliographiccitation.journal","Journal of Medicinal Chemistry"],["dc.bibliographiccitation.lastpage","4253"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Brands, M."],["dc.contributor.author","Endermann, R."],["dc.contributor.author","Gahlmann, R."],["dc.contributor.author","Kruger, J."],["dc.contributor.author","Raddatz, S."],["dc.contributor.author","Stoltefuss, J."],["dc.contributor.author","Belov, Vladimir N."],["dc.contributor.author","Nizamov, S."],["dc.contributor.author","Sokolov, Viktor V."],["dc.contributor.author","Meijere, Armin de"],["dc.date.accessioned","2018-11-07T10:03:05Z"],["dc.date.available","2018-11-07T10:03:05Z"],["dc.date.issued","2002"],["dc.description.abstract","The natural dipeptide antibiotic TAN 1057 A,B displays excellent antibacterial activity against staphylococci including methicillin resistant Staphylococcus aureus. However, the in vitro activity against additional Gram-positive strains, in particular pneumococci and Enterococcus faecalis, proved to be considerably lower. We report the synthesis and pharmacological evaluation of new derivatives of this natural product that displayed increased antibacterial potency against staphylococci and were also active against pneumococci. In particular, the analogues bearing modified beta-homoarginine side chains with methylated guanidine moieties were shown to be significantly more potent than the natural product TAN 1057 A,B."],["dc.identifier.doi","10.1021/jm0111191"],["dc.identifier.isi","000177913500015"],["dc.identifier.pmid","12213065"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38370"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0022-2623"],["dc.title","Novel antibiotics for the treatment of gram-positive bacterial infections"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","509"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Langenbeck s Archives of Surgery"],["dc.bibliographiccitation.lastpage","519"],["dc.bibliographiccitation.volume","402"],["dc.contributor.author","Dango, Sebastian"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Weiss, Elisabeth"],["dc.contributor.author","Hosseini, Ali Seif Amir"],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beham, Alexander Wilhelm"],["dc.date.accessioned","2018-11-07T10:24:29Z"],["dc.date.available","2018-11-07T10:24:29Z"],["dc.date.issued","2017"],["dc.description.abstract","Upper GI bleeding remains one of the most common emergencies with a substantial overall mortality rate of up to 30%. In severe ill patients, death does not occur due to failure of hemostasis, either medical or surgical, but mainly from comorbidities, treatment complications, and decreased tolerated blood loss. Management strategies have changed dramatically over the last two decades and include primarily endoscopic intervention in combination with acid-suppressive therapy and decrease in surgical intervention. Herein, we present one of the largest patient-based analysis assessing clinical parameters and outcome in patients undergoing endoscopy with an upper GI bleeding. Data were further analyzed to identify potential new risk factors and to investigate the role of surgery. In this retrospective study, we aimed to analyze outcome of patients with an UGIB and data were analyzed to identify potential new risk factors and the role of surgery. Data collection included demographic data, laboratory results, endoscopy reports, and details of management including blood administration, and surgery was carried out. Patient events were grouped and defined as \"overall\" events and \"operated,\" \"non-operated,\" and \"operated and death\" as well as \"non-operated and death\" where appropriate. Blatchford, clinical as well as complete Rockall-score analysis, risk stratification, and disease-related mortality rate were calculated for each group for comparison. Overall, 253 patients were eligible for analysis: endoscopy was carried out in 96% of all patients, 17% needed surgical intervention after endoscopic failure of bleeding control due to persistent bleeding, and the remaining 4% of patients were subjected directly to surgery. The median length of stay to discharge was 26 days. Overall mortality was 22%; out of them, almost 5% were operated and died. Anticoagulation was associated with a high in-hospital mortality risk (23%) and was increased once patients were taken to surgery (43%). Patients taking steroids presented with a risk of death of 26%, once taken to surgery the risk increased to 80%. Patients with liver cirrhosis had a risk of death of 42%; we observed a better outcome for these patients once taken to theater. Clinically, once scored with Blatchford score, statistical correlation was found for initial need for blood transfusion and surgical intervention. Clinical as well as complete Rockall score revealed a correlation between need for blood transfusion as well as surgical intervention in addition with a decreased outcome with increasing Rockall scores. Risk factor analysis including comorbidity, drug administration, and anticoagulation therapy introduced the combination of tumor and non-steroidal antirheumatic medication as independent risk factors for increased disease-related mortality. UGIB remains challenging and endoscopy is the first choice of intervention. Care must be taken once a patient is taking antirheumatic non-steroidal pain medication and suffers from cancer. In patients with presence of liver cirrhosis, an earlier surgical intervention may be considered, in particular for patients with recurrent bleeding. Embolization is not widely available and carries the risk of necrosis of the affected organ and should be restricted to a subgroup of patients not primarily eligible for surgery once endoscopy has failed. Taken together, an interdisciplinary approach including gastroenterologists as well as surgeons should be used once the patient is admitted to the hospital to define the best treatment option."],["dc.identifier.doi","10.1007/s00423-017-1552-2"],["dc.identifier.isi","000400365500012"],["dc.identifier.pmid","28091770"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42673"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1435-2451"],["dc.relation.issn","1435-2443"],["dc.title","Relevance of surgery in patients with non-variceal upper gastrointestinal bleeding"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","220"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Gut"],["dc.bibliographiccitation.lastpage","227"],["dc.bibliographiccitation.volume","55"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Haller, Florian"],["dc.contributor.author","Radzun, H.-J."],["dc.date.accessioned","2018-11-07T10:22:30Z"],["dc.date.available","2018-11-07T10:22:30Z"],["dc.date.issued","2006"],["dc.description.abstract","Background and aims: Activation of T cells by dendritic cells ( DC) is thought to play a pivotal role in induction and maintenance of Crohn's disease. Detailed analyses however concerning the phenotype and maturation of DC as well as the mechanisms underlying their recruitment are still lacking for Crohn's disease. Methods: Different myeloid and plasmacytoid DC subsets were characterised by immunohistochemistry. Expression of the so-called \"lymphoid' chemokines CCL19, CCL20, and CCL21 was determined by real time reverse transcription-polymerase chain reaction in Crohn's disease and normal controls. Furthermore, expression of CCL19, CCL20, and CCL21 as well as their receptors CCR6 (for CCL20) and CCR7 (for CCL19 and CCL21) was characterised by immunohistochemistry and, in addition, their cellular localisation was determined by double immunofluorescence investigations. Results: Colonic tissue affected by Crohn's disease was characterised by an increased number of mature myeloid DC forming clusters with proliferating T cells. In keeping with their advanced maturation, DC possess the chemokine receptor CCR7. Increased expression of the CCR7 ligands CCL19 by DC themselves as well as CCL21 by reticular cells and lymphatic vessels was observed in Crohn's disease, thereby causing the matured DC to be trapped at the site of inflammation. Conclusion: Our results demonstrate that autocrine and paracrine actions of lymphoid chemokines in Crohn's disease may lead to increased numbers of mature DC away from their usual migration to lymphoid organs and result in the development of a tertiary lymphatic tissue within the bowel wall maintaining the autoimmune inflammation in Crohn's disease."],["dc.identifier.doi","10.1136/gut.2004.063008"],["dc.identifier.isi","000234553500019"],["dc.identifier.pmid","16118351"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42291"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","B M J Publishing Group"],["dc.relation.issn","0017-5749"],["dc.title","Increased number of mature dendritic cells in Crohn's disease: evidence for a chemokine mediated retention mechanism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","209"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","OSTEOLOGIE"],["dc.bibliographiccitation.lastpage","216"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Cortis, Judith"],["dc.contributor.author","Claus, Ch."],["dc.contributor.author","Funke, M."],["dc.contributor.author","Nolte, W."],["dc.contributor.author","Huefner, Michael"],["dc.contributor.author","Raddatz, Dirk"],["dc.date.accessioned","2018-11-07T08:35:18Z"],["dc.date.available","2018-11-07T08:35:18Z"],["dc.date.issued","2009"],["dc.description.abstract","Crohn's disease (CD) is associated with reduced bone mineral density and increased fracture risk. To assess the effects of the inflammatory process itself on bone parameters, we investigated patients with active CD and in remission without glucocorticoid treatment four weeks prior to analysis. Patients with active CD were compared to age- and sex-matched healthy volunteers and osteoporosis patients. Bone mineral density, bone formation and resorption markers were assessed, in addition to simple inflammatory markers and cytokines. Out of seven patients with active disease, three had osteopenia and one osteoporosis (WHO definition). The erythrocyte sedimentation rate (ESR) was associated with BMD at the femoral neck (R(2) = 0.853, p<0.01) and the spine (R(2)=0.772, p<0.05). ESR seems to influence bone formation, as shown by lower bone alkaline phosphatase with high ESR (R(2)=0.725, R=-0.852, p<0.05). The clinical disease activity score was not useful in determining patients' risk of acquiring bone disease. in conclusion, in patients with Crohn's disease, the degree of the inflammatory process as assessed by ESR indicates bone loss and might be of value in identifying patients at risk of developing osteoporosis."],["dc.identifier.isi","000271412000009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18032"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Verlag Hans Huber"],["dc.relation.issn","1019-1291"],["dc.title","Erythrocyte sedimentation rate as an osteoporosis risk factor in patients with active Crohn's disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","389"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","European Journal of Gastroenterology & Hepatology"],["dc.bibliographiccitation.lastpage","395"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Wietzke-Braun, Perdita"],["dc.contributor.author","Schindler, C."],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Braun, F."],["dc.contributor.author","Armbrust, T."],["dc.contributor.author","Nolte, W."],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T10:49:51Z"],["dc.date.available","2018-11-07T10:49:51Z"],["dc.date.issued","2004"],["dc.description.abstract","Objective Patients with non-resectable liver metastases of colorectal cancer have poor prognosis and are mainly treated by palliative chemotherapy. Laser interstitial thereto-therapy is an innovative minimal invasive procedure for local tumour destruction within solid organs. The aim of the study was to investigate quality of life and outcome of ultrasound-guided laser interstitial thermotherapy (US-LITT) in patients with liver metastases of colorectal cancer. Methods In this prospective non-randomized study, 45 patients with liver metastases of colorectal cancer were palliatively treated by US-LITT. Patient survival was analysed by the Kaplan-Meier method and the quality of life by questionnaire C30 of the European Organisation for Research and Treatment of Cancer before, and 1 week, 1 month, and 6 months after initiation of US-LITT. Results Median survival after initiation of US-LITT was 8.5 +/- 0.7 months with a range of 1.5-18 months. Body weight was constant 1 month after US-LITT. In the multivariate analyses, quality-of-life symptoms and functioning scales did not deteriorate in patients alive at 6 months after initiation of US-LITT. Univariate analyses outlined a significant increase of the pain subscale before and at 1 week after US-LITT. Conclusions This study first describes the quality of life in patients with liver metastases of colorectal cancer treated by US-LITT. Potential benefits of the minimal invasive procedure could be prolonged survival time by preserved quality of life, but this first impression needs to be verified in a comparative study."],["dc.identifier.doi","10.1097/00042737-200404000-00004"],["dc.identifier.isi","000220655900004"],["dc.identifier.pmid","15028971"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48527"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0954-691X"],["dc.title","Quality of life and outcome of ultrasound-guided laser interstitial thereto-therapy for non-resectable liver metastases of colorectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","162"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Radiation Research"],["dc.bibliographiccitation.lastpage","169"],["dc.bibliographiccitation.volume","169"],["dc.contributor.author","Moriconi, Federico"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Dudas, Joszef"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Rave-Fraenk, Mararet"],["dc.contributor.author","Sheikh, Nadeem"],["dc.contributor.author","Saile, Bernhard"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T11:18:56Z"],["dc.date.available","2018-11-07T11:18:56Z"],["dc.date.issued","2008"],["dc.description.abstract","The aim of the study was to analyze the effect of a single irradiation on chemokine gene expression in the rat liver and in isolated rat hepatocytes. RNA extracted from livers and from hepatocytes within the first 48 h after irradiation was analyzed by real-time PCR and the Northern blot assay. The chemokine concentrations in the serum of irradiated rats were measured quantitatively by ELISA. A significant radiation-induced increase of CINC1, IP10, MCP1, MIP3 alpha, MIP3 beta, MIG and ITAC gene expression could be detected at the RNA level in the liver. CINC1, MCP1 and IP10 serum levels were significantly increased. In rat hepatocytes in vitro, only MIP3a showed a radiation-induced increase in expression, while CINC1, IP10, MIP3 beta, MIG, MIP1 alpha, ITAC and SDF1 RNA levels were significantly down-regulated. However, incubation of irradiated hepatocytes in vitro with either TNF-alpha, IL1 beta, or IL6 plus TNF-alpha led to up-regulation of MCP1, IP10 and MCP1 or CINC1 and MIP3 beta, respectively. Irradiation of the liver induces up-regulation of the genes of the main proinflammatory chemokines, probably through the action of locally synthesized proinflammatory cytokines. The reason for the lack of liver inflammation in this model has still to be clarified. (C) 2008 by Radiation Research Society."],["dc.identifier.doi","10.1667/RR1006.1"],["dc.identifier.isi","000252633000004"],["dc.identifier.pmid","18220462"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55150"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Radiation Research Soc"],["dc.relation.issn","0033-7587"],["dc.title","Effect of radiation on gene expression of rat liver chemokines: In vivo and in vitro studies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","166"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Laboratory Investigation"],["dc.bibliographiccitation.lastpage","177"],["dc.bibliographiccitation.volume","92"],["dc.contributor.author","Moriconi, Federico"],["dc.contributor.author","Malik, Ihtzaz Ahmed"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Blaschke, Martina"],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Khan, Sajjad"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T09:14:00Z"],["dc.date.available","2018-11-07T09:14:00Z"],["dc.date.issued","2012"],["dc.description.abstract","Chronic inflammatory bowel diseases can be successfully treated with antibodies against the acute phase mediator TNF-alpha. The process of activation and of extravasation of inflammatory cells from the blood into the 'stressed' tissue site is controlled by cytokines and chemokines, which attract leukocytes and by adhesion molecules, which mediate their attachment and transmigration toward the affected cell(s). The changes in the gene expression of adhesion molecules taking place in those cells before attachment have been less investigated. Changes of PECAM-1, ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1) gene expression were studied in phytohaemagglutinin (PHA)- and lipolysaccharide (LPS)-treated human peripheral blood leukocytes (PBLs), granulocytes and the human monocyte cell line U-937. Cells were treated either with PHA or with LPS in the presence or absence of infliximab and incubated with TNF-alpha, IFN-gamma and/or transforming growth factor beta (TGF-beta) and treated as above. Activation of PBLs by PHA or LPS treatment triggered a sharp upregulation of ICAM-1, VCAM-1 gene expression and a time-dependent downregulation of PECAM-1 gene expression reaching a minimum 4 h from start of the experiment. The anti-TNF-alpha antibody infliximab, by neutralizing TNF-alpha and IFN-gamma production, completely reversed PECAM-1 mRNA downregulation and ICAM-1 and VCAM-1 upregulation. Immunostaining of PBLs cytospins with antibodies against PECAM-1 and ICAM-1 confirmed RT-PCR and western blot results. PBLs IFN-gamma or TNF-alpha treatment downregulated PECAM-1 in parallel with the upregulation of ICAM-1 and VCAM-1 gene expression, whereas TGF-beta upregulated PECAM-1- and downregulated ICAM-1 and VCAM-1 gene expression counteracting the effect of TNF-alpha or IFN-gamma. Similar results were obtained in human U937 cells and in granulocyte cultures by TNF-alpha or IFN-gamma treatment. Taken together, these results suggest that infliximab, blocking TNF-alpha and IFN-gamma production, exerts its anti-inflammatory effect through inhibiting downregulation of PECAM-1 gene expression and upregulation of ICAM-1 and VCAM-1 expression in leukocytes of the peripheral blood. These results also suggest that TGF-beta may thus be of therapeutic importance as an anti-inflammatory agent. Laboratory Investigation (2012) 92, 166-177; doi:10.1038/labinvest.2011.160; published online 31 October 2011"],["dc.identifier.doi","10.1038/labinvest.2011.160"],["dc.identifier.isi","000299799700001"],["dc.identifier.pmid","22042082"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27298"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","0023-6837"],["dc.title","The anti-TNF-alpha antibody infliximab indirectly regulates PECAM-1 gene expression in two models of in vitro blood cell activation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Bone"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Eidner, T."],["dc.contributor.author","Lehmann, G."],["dc.contributor.author","Viereck, Volker"],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Hein, G."],["dc.contributor.author","Hufner, M."],["dc.date.accessioned","2018-11-07T09:05:34Z"],["dc.date.available","2018-11-07T09:05:34Z"],["dc.date.issued","2001"],["dc.format.extent","S140"],["dc.identifier.isi","000168825000317"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25351"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.issn","8756-3282"],["dc.title","Cytokines, osteoprotegerin and osteoprotegerin-ligand in vitro and histomorphometric indices of bone formation in patients with different bone diseases"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]